The intent of this National Institutes of Healthsponsored study was to compare a belatacept-based immunosuppressive regimen with a maintenance regimen of tacrolimus and mycophenolate. Nineteen primary, Epstein-Barr virus-immune renal transplant recipients with a negative cross-match were randomized to one of three groups. All patient groups received perioperative steroids and maintenance mycophenolate mofetil. Patients in groups 1 and 2 were induced with alemtuzumab and maintained on tacrolimus or belatacept, respectively. Patients in group 3 were induced with basiliximab, received 3 mo of tacrolimus, and maintained on belatacept. There was one death with a functioning allograft due to endocarditis (group 1). There were three graft losses due to vascular thrombosis (all group 2) and one graft loss due to glomerular disease (group 1). Biopsy-proven acute cellular rejection was more frequent in the belatacept-treated groups, with 10 treated episodes in seven participants compared with one episode in group 1; however, estimated GFR was similar between groups at week 52. There were no episodes of posttransplant lymphoproliferative disorder or opportunistic infections in any group. Protocol enrollment was halted prematurely because of a high rate of serious adverse events. Such negative outcomes pose challenges to clinical investigators, who
Introduction
Over the past three decades, there has been a dramatic improvement in the 1-year graft survival of transplanted kidneys and a concomitant decrease in the incidence of acute rejection (1) . Although improvements in surgical technique, organ preservation, and donor management have contributed to these improvements, there can be no disputing the critical impact of improved immunosuppressive agents and regimens. Nevertheless, despite significantly better short-term outcomes, long-term outcomes following kidney and extrarenal transplantation have remained relatively stagnant (2, 3) . Many factors contribute to premature graft loss, including the increasing age of organ donors, the increasing medical complexity of transplant recipients, and medication nonadherence; however, there is widespread consensus that the very immunosuppressive agents that are responsible for the excellent short-term outcomes in transplantation contribute significantly to impaired long-term graft survival and patient morbidity and mortality.
Both calcineurin inhibitors (CNIs) and corticosteroids contribute to development and severity of hypertension, new-onset diabetes after transplantation, and dyslipidemia. These events in turn promote the development of cardio-and cerebro-vascular disease, which are two of the major causes of morbidity and mortality following organ transplantation (4) . In addition, CNIs have known nephrotoxic effects (5) . Although the exact contributions of CNIs to chronic injury of transplanted kidneys remains controversial (6, 7) , there is no doubt that CNIs are nephrotoxic and have the potential to cause significant renal injury, even in the native kidneys of extrarenal transplant recipients (8) .
Given these known toxicities, there has been intense interest in developing immunosuppressive regimens that avoid long-term use of CNIs, but such studies have met with varying success (reviewed by Casey and MeierKriesche [9] ). With the advent of costimulatory blockade agents and in light of promising results in preclinical models, there has been new interest in CNI avoidance. Early published results using belatacept regimens demonstrated safety and efficacy for the prophylaxis of acute rejection (10) . Further investigation in phase 3 studies using both standard and extended criteria donors (Benefit and Benefit-EXT) demonstrated that belatacept-treated groups had significantly higher rates of acute cellular rejection at 1 year (11, 12) but significantly better renal function up to 7 years after transplant (13) . Offsetting these advantages, the use of belatacept in combination with nondepleting induction therapy was associated with increased incidence and severity of acute cellular rejection, as well as posttransplant lymphoproliferative disorder, which was seen primarily in Epstein-Barr virus (EBV)-seronegative recipients.
To this end, we developed a clinical trial (Clinical Trials in Organ Transplant-10 [CTOT-10]) to further understand the optimal implementation and outcomes of belatacept therapy in a population of deceased and living donor kidney transplant recipients. To mitigate the risk of cellular rejection, the study utilized a belatacept-based regimen incorporating immunosuppressive induction therapy with a depletional agent together with either progressively withdrawn or absent CNI. The primary outcome of interest was renal function at 1 year after transplantation; however, because of a high number of serious adverse events (SAEs), the trial was halted early to further enrollment. These events demonstrate the responsibility of investigators to their study participants in weighing the risks and benefits of experimental therapy.
Methods

Study design
The CTOT-10 ("Optimization of NULOJIX (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation," ClinicalTrials.gov identifier NCT01436305; Investigational New Drug application 111,783) was a 3-year randomized prospective trial conducted at three transplant centers in the United States ( Figure 1 ). Enrollment began in November 2011, and primary outcomes were prespecified to be analyzed at 12 mo 
Investigational therapy, dosing, and study arms
The study consisted of three arms ( Figure 1A ): In group 1, recipients received alemtuzumab induction, rapid methylprednisolone taper, and maintenance tacrolimus and mycophenolate mofetil. Group 2 received alemtuzumab induction, rapid methylprednisolone taper, and maintenance belatacept and mycophenolate mofetil. As a control for the use of depletional induction in groups 1 and 2, nondepletional induction with basiliximab was given using a standard dosing regimen with rapid methylprednisolone taper, a 3-mo course of tacrolimus, and maintenance belatacept and mycophenolate in group 3. Specific dosing and timing of therapy are shown in Table 1 .
The investigational drug used in this trial was Nulojix (belatacept; National Drug Code 0003-0371-13). Nulojix is manufactured by Bristol-Myers Squibb (BMS; Princeton, NJ) and was supplied as 250-mg intravenous infusion-only vials (BMS lot numbers 1F65900, 1L66659, 3E77131, 4A83805, 4A82606, and 4B79981). The total infusion dose of Nulojix was based on actual body weight at the time of transplantation and not modified over the course of the study unless there was a change in body weight >10%. Participants received Nulojix 10 mg/kg on day 0 (day of transplant) and then on days 4, 14, 28, 56, and 84. After day 84, participants received a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
Participants
Patients aged 18-65 years who received a first-time kidney transplant from a living or deceased donor were considered eligible for enrollment (Table 2) . Key exclusion criteria included prior or multiorgan transplant, elevated panel reactive antibody >30%, EBV-seronegative recipients, and individuals at risk of recurrence of their renal disease.
Hypothesis and outcome measures
The hypothesis of this trial was that steroid-free belatacept-based immunosuppressive regimens using induction with either alemtuzumab or basiliximab and tacrolimus would achieve superior renal function with comparable rates of rejection compared with a tacrolimus-based maintenance immunosuppressive regimen. The primary outcome measure was mean GFR calculated for each treatment group using the Chronic Kidney Disease Epidemiology Collaboration Equation at 52 weeks after transplantation (14) . Secondary outcome measures were histologic evidence of acute rejection with graft dysfunction in the first 24 weeks of treatment and other measures of renal function and injury at 52, 104, and 156 weeks of treatment. Measurements of cardiovascular and metabolic parameters such as new-onset diabetes or impaired fasting glucose at 52 weeks, the incidence of treated diabetes, hemoglobin A1c measurements, and fasting lipid profiles were also included as secondary end points.
Safety outcome measures
An independent DSMB assessed cumulative safety and efficacy data throughout the trial and provided NIAID with recommendations about study continuation. Safety events of interest included the incidence of death or graft loss, incidence of rejection, and the incidence of all adverse events and SAEs. Moreover, we focused on any infections requiring hospitalization or systemic therapy and specifically performed surveillance for BK and cytomegalovirus (CMV) viremia (locally monitored) and EBV infections.
Other secondary end points
Mechanistic assays were performed on specimens collected before transplant, then on days 28 and 84, as well as weeks 24, 36, 52, 72, 104, and 156 after transplant. These included measures of immune reactivity and immune function. Because of the small number of participants enrolled, the results of these studies will not be addressed in this report.
Statistical analysis
Because the trial was terminated early for safety reasons with only 19 participants randomized, only summary descriptive statistics are reported. Categorical variables are summarized with counts and percentages, and continuous variables are summarized with medians and ranges. Calculated GFR is displayed graphically in dot plots at 52 weeks and longitudinally in line plots by treatment group. Kaplan-Meier plots are presented to depict graft survival and rejection-free survival to compare the treatment groups.
Results
A total of 19 participants were enrolled in the study, and their demographic characteristics are outlined in Table 3 . Six participants were enrolled in each group for groups 1 and 2, and seven participants were enrolled in group 3. The majority were living donor recipients (68.4%), and 42% were black, representative of the predominance of the study centers in the Southeast. Groups were fairly balanced demographically. Median follow-up was 1091 days (range 23-1177 days).
Kidney graft survival is shown in Figure 2 . There were five graft losses overall. In group 1, there was one death with a functioning allograft due to staphylococcal bacteremia and endocarditis and one allograft loss caused by collapsing glomerulopathy on day 382. There was no conclusive evidence that viral infection mediated the glomerular injury. There were three allograft losses in group 2, all attributed to vascular thrombosis and technical injury. In one case, dissection of the recipient's external iliac artery, attributed to a proximal vascular clamp injury, was detected at 1.5 weeks after an uneventful living related donor kidney transplant. This participant was taken to the operating room, where the kidney was explanted and flushed, a Gortex interposition graft placed, and the kidney reimplanted. Although persistent perfusion was documented by Doppler ultrasound, the graft never regained function. In the second case, a living related donor transplant was performed preemptively. Intraoperatively, there was low-grade fever and mild hypotension that persisted postoperatively. Doppler ultrasound of the allograft on posttransplant day 1 showed absent flow in the renal vein, consistent with a renal vein thrombosis. Reexploration confirmed vascular thrombosis but failed to reveal a technical cause. Despite thrombectomy and anticoagulation, meaningful flow could not be reestablished, and the graft was removed. The third participant, who had end-stage renal disease cause by polycystic kidney disease, received a standard criteria deceased donor allograft and had significant intraoperative fever and hypotension. Doppler ultrasound demonstrated no flow in the immediate postoperative period. Reexploration demonstrated patent vessels but with poor perfusion secondary to an arterial platelet plug. Despite thrombectomy and anticoagulation, a nephrectomy was ultimately performed, and intraoperative assessment revealed renal vein thrombosis with compression of the inferior vena cava due to a large polycystic kidney. Following native nephrectomy to relieve inferior vena cava (IVC) compression, the patient was subsequently successfully retransplanted. Finally, there was one intraoperative thrombosis in control group 1, and this was managed successfully with intraoperative thrombectomy and heparinization, with excellent graft function postoperatively.
In the control arm of group 1, three participants had allograft biopsies for allograft dysfunction; only borderline inflammation was detected, and only one of these episodes was treated with additional immunosuppression (Table 4 ). In contrast, seven participants in groups 2 and 3 developed rejection (53.8%), with 10 episodes of rejection (two participants in group 2 and five in group 3). In these belatacept-treated groups, one rejection episode was considered borderline grade, and Banff grade 2A and 2B grades of rejection were more frequently seen. These episodes responded to treatment with pulse corticosteroids (two cases in group 2 and three cases group 3) or rabbit anti-thymocyte globulin (ATG) in combination with pulse corticosteroids (one case in group 2 and three cases in group 3). In one group 2 participant with Banff 1A cellular rejection on day 224, there were findings suspicious for antibody-mediated rejection but without detectable donor-specific antibody (DSA). This participant was treated with pulse steroids, a change in the maintenance immunosuppression regimen to tacrolimus with increased mycophenolate mofetil and a prednisone taper. One episode of rejection was not treated because the biopsy findings were assessed as residual signs of rejection from a prior treatment episode. As shown in Figure 3 , two of five rejection episodes occurred within 21 days of weaning from tacrolimus (group 3) with another occurring >1 year after weaning. Following antirejection treatment, there were no substantial falls in estimated GFR (eGFR) in those participants with rejection who retained their grafts ( Figure 3B ), and there were no cases of graft loss due to acute rejection. DSAs were not detected in any study participant during the follow-up period. Finally, rejection episodes were not related to immunosuppressive reductions in the setting of opportunistic infections (data not shown). Renal function, censored for graft loss at 1 year, was excellent ( Figure 3A) . In group 1, eGFR was 55.9 AE 8.9 mL/min and similar in group 2 (51.6 AE 23.5 mL/min) and group 3 (58.3 AE 12.2 mL/min; p-value not significant). Furthermore, over the course of the study, there were no significant decreases in eGFR in any group (Figure 3B) , with the exception of the single group 1 participant who experienced graft failure on day 382 due to collapsing glomerulopathy. In participants in the belatacept groups with rejection, eGFR was similar to that in nonrejecters (data not shown). There were no cases of posttransplant lymphoproliferative disorder or progressive multifocal leukoencephalopathy. BK viremia was seen more frequently in group 3 (three cases) with one case each in groups 1 and 2. CMV was infrequent and present in two participants, one in group 1 and one in group 3. There were no cases of BK polyomavirus nephropathy. Other common adverse events were similar across all treatment groups.
On March 29, 2012, the study team paused enrollment in study arm 2 because of thrombotic SAEs. On April 20, 2012, the study team, with the concurrence of the DSMB, halted further enrollment in the study because of • Female participants of childbearing potential must have a negative pregnancy test on study entry • Female and male participants with reproductive potential must agree to use FDA-approved methods of birth control during participation in the study and for 4 mo following completion of the study • Flow-based PRA within the last 12 months (in absence of a sensitizing event) <30%, as determined by each participating study center; if the participant experienced a sensitizing event after the PRA test date, then the PRA must be repeated and confirmed <30% • Negative cross-match or PRA of 0% on historic and admission sera, as determined by each participating study center • A documented negative TB test within the 12 months prior to transplant; if documentation is not present at the time of transplantation and the participant does not have any risk factors for TB, a TB-specific interferon c release assay may be performed the number of rejection events in arms 2 and 3. All active study participants continued to be followed for safety on their current therapy, as outlined in the original study protocol.
Discussion
The optimization of long-term transplant outcomes remains a challenge. Critical to late graft loss are the contributions of both chronic kidney injury in about half of recipients and death with a functioning graft (15) . In the latter, cardiovascular disease is the most common cause of death, followed by infection and malignancy. The identification of immunosuppressive therapies (i) that mitigate rejection episodes that can lead to late kidney allograft failure, (ii) that suppress potent DSA responses, and (iii) that do not contribute to kidney injury and cardiovascular disease remains challenging. The goal of this study was to optimize the use of a promising agent that appeared, in early phase studies, to provide an opportunity for CNIfree therapy. Although we fully recognize that, because of the limited enrollment, it is not possible to draw conclusions about the safety or efficacy of the alternative treatment regimens, we felt an obligation to inform those working in the field of the issues encountered in the conduct of this trial.
An unexpected occurrence was the frequency of graft thrombosis in recipients randomized to arm 2. A clear concern was that the infusion of two protein compounds (alemtuzumab and belatacept) in close temporal proximity during reperfusion might have engendered a prothrombotic state. Although we cannot exclude this, a review of the events indicated that technical issues contributed to at least two of the cases (distal dissection related to a vascular clamp and renal vein thrombosis related to compression of the IVC). The thromboembolic events were dissimilar enough to each other that there may have been no unifying explanation. Furthermore, prior reports of treatment with either rabbit ATG (16) or alemtuzumab (17) in combination with belatacept have not identified an association with allograft thrombosis, although in both instances, the agents were temporally separated by 24 h. Although technical issues were strongly implicated in two of the three vascular thrombotic events, the extremely high incidence of perioperative adverse vascular events understandably influenced the DSMB's decision to halt enrollment. This decision exemplifies the valuable role of the interaction among DSMB, study monitors, and investigators in conducting safe and effective clinical trials when a high incidence of adverse events makes it unlikely that an experimental intervention can emerge from statistical and clinical analysis without major clinical uncertainties or reservations (18) .
There was a high rate of acute cellular rejection in the belatacept groups, and although high-grade rejections were seen, these were reversed with steroids or rabbit ATG without subsequent graft failure. Such findings suggest that a more prolonged wean may be necessary in the first year after transplantation as well as close monitoring of those individuals. The currently ongoing Belatacept Early Steroid Withdrawal Trial includes >200 kidney transplant recipients, and aggregate cellular rejection rates were not apparently elevated when combining belatacept with lymphocyte-depletional agents (19) . Ultimately, it would be critical to identify treatment-specific risk factors for rejection because the participants of this study would be considered to have low immunological risk, except for black race, although all participants had relatively low calculated panel reactive antibody and no DSA at the time of transplantation. Recent work by Espinosa et al (20) identified a novel population of CD4 memory T cells that are present prior to transplantation and that appear to predict an increased risk of rejection in patients maintained on a belatacept-based regimen. This work requires additional validation but may indicate a patient population at increased risk of rejection when using belatacept in place of a CNI.
Concerns about the increased incidence and severity of acute cellular rejection have limited the enthusiasm for belatacept when used according to the product label. For some, these events overshadow the potential benefits of this agent with respect to renal function and the cardiovascular risk profile. Although our numbers preclude any concrete conclusions, larger clinical trials have documented a persistent improvement in recipient allograft function over years in belatacept-treated patients compared with those treated with cyclosporine (21), as well as a lack of donor-specific HLA antibody (13) . Although it is conceivable that the improved adherence resulted from an infused immunosuppressive agent and possibly greater exposure to mycophenolic acid compared with cyclosporine-based maintenance regimens, further preclinical and recent clinical studies have demonstrated a potent inhibitory effect of blockade of the CD28/CD80/CD86 pathway on B cell function (22) . These features of this agent are of the utmost clinical relevance as long-term antibody injury is a critical contributor to late kidney allograft failure. To this end, a new study of belatacept in renal transplant recipients, designed to address both the potential thrombotic complications and the increased rates of acute cellular rejection, is under way (CTOT-16, ClinicalTrials.gov identifier NCT01856257).
